This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • A second-line, single arm, phase II clinical study...
Clinical trial

A second-line, single arm, phase II clinical study with tremelimumab, a fully humanized anti-CTLA-4 monoclonal antibody, as monotherapy in patients with unresectable malignant mesothelioma

Read time: 1 mins
Last updated:3rd Aug 2012
To assess the rate of objective clinical complete response (CR) or partial response (PR)
Category Value
Study start date 2012-08-03

View full details